The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.60
Ask: 13.90
Change: 0.15 (1.10%)
Spread: 0.30 (2.206%)
Open: 13.60
High: 13.75
Low: 13.75
Prev. Close: 13.60
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Kingswood cuts outlook; Poolbeg in patent joy

Mon, 02nd Oct 2023 14:20

(Alliance News) - The following is a round-up of updates by London-listed companies, issued last week and not separately reported by Alliance News:

----------

Kingswood Holdings Ltd - wealth manager - Cuts profit guidance. Kingswood's revenue in the half-year ended June 30 declines 22% to GBP80.4 million from GBP62.7 million and its pretax loss widens to GBP9.9 million from GBP1.7 million. Kingswood cuts its proforma operating profit guidance to GBP13.6 million from GBP14.7 million, due to lower than expected investment banking and capital markets activity.

----------

Poolbeg Pharma PLC - London-based infectious disease focused biopharmaceutical company - Says hearing with European Patent Office related to Immunomodulator I, one of its European patents, has been cancelled. "This favourably concludes this matter with the patent maintained as granted," Poolbeg adds.

----------

PHSC PLC - Kent-based health, safety, hygiene and environmental consultancy services provider - Says revenue for five-months ended August 31 falls to just shy of GBP1.4 million from GBP1.4 million a year prior. Earnings before interest, tax, depreciation, and amortisation down to GBP139,000, from GBP144,000. "This was caused by the lower revenues not being fully offset by reduced costs and the pay increases referred to above," PHSC says.

----------

Looking Glass Labs Ltd - specialises in metaverse, play-to-earn tokenisation and blockchain monetisation - Plans share consolidation. Every 75 shares to be consolidated into one share.

----------

Grand Vision Media Holdings PLC - out-of-home advertising and digital marketing company - Revenue in six months to June rises 21% to HKD2.3 million, around GBP237,829, from HKD1.9 million a year prior. Pretax loss narrows to HKD2.0 million from HKD2.3 million. Company says: "After the 3-year period shroud by Covid-19, the world enters a new post-pandemic era in 2023. However, the general market outlook continue to present many challenges due to tightening economic conditions in China and other global economies. We continue to diversify and look for new revenue streams and business models to augment our core marketing services. The new initiative of international brand management and expansion whereby we help brands expand to new geographies is progressing and we expect to generate revenue from this in the second half of the year. In particular, we will be working closely with our Korean and Thai customers to increase cross-border ecommerce."

----------

KR1 PLC - investor focused on the blockchain industry - Net asset value per share rises 67% year-on-year to 51.1 pence per share at its June 30 half-year end. NAV per share is 30% higher from December 31. "With some positive market momentum as well as major new investments that were announced since the year-end, the company's net assets have grown substantially to GBP90.7 million at the end of June, providing shareholders with capital growth, which remains our main long-term focus. The year-on-year decline in income from digital assets, driven by various factors, including stagnant prices over the relevant period, was expected, while still being of great benefit to the company."

----------

VVV Resources Ltd - investor focused on identifying opportunities in the precious metals and base metals sector - Pretax loss in half-year to June 30 narrows to GBP62,000 from GBP77,000 a year prior. Loss is solely down to administrative costs, which decline 19% to GBP62,000. Posts no revenue, unchanged from prior year.

----------

Octopus Titan VCT PLC - venture capital trust - Says will raise maximum of GBP125 million, with an over-allotment facility worth GBP75 million, in planned offer for subscription.

----------

One Heritage Group PLC - UK-based residential developer focused on the north of England - Completes sale of remaining 15 units at Lincoln House, Bolton, ahead of updated deadline of October 9. "The funds have been received in full, including an interest payment that the buyer had to pay," it says. In addition, One Heritage says Anthony Unsworth resigns as chief financial officer. One Heritage adds: "Anthony will continue in his role as CFO and executive director during his notice period during the next six months. The company has already begun speaking with its contacts in the headhunter world and has started the process of finding the right person for the next leg of the growth in the business."

----------

Cavendish Financial PLC - London-based stockbroker - Says trading in the City was "quiet during the summer", though Cavendish, established on September 8 via the merger of finnCap and Cenkos, has been busy since forming. Cavendish Financial adds: "Since merger completion the group has already announced a number of significant transactions which will close in the coming months including acting as sole adviser to Round Hill Royalty Fund Ltd on its offer from Concord Cadence Ltd, fundraisings for Haydale Graphene PLC and Shield Therapeutics plc and obtaining key regulatory clearances for the equity financing of Allergy Therapeutics by ZQ Capital and Southern Fox."

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
20 Jul 2022 12:04

IN BRIEF: Poolbeg Pharma shares rise as first human trial begins

Poolbeg Pharma PLC - London-based pharmaceutical company - Receives approval to commence its Lipopolysaccharide human clinical trial for POLB 011, a drug that aims to treat severe influenza. The trial will formally start on Friday. It will assess POLB 011 in damping the immune response to lipopolysaccharide, which acts as a surrogate for the hyperinflammatory response associated with severe influenza. Initial results are expected in the final quarter of 2022. Poolbeg says at that point it intends to "rapidly" monetise by out-licensing and/or partnering with pharmaceutical and biotechnology companies for the drug's further development.

Read more
27 Jun 2022 10:47

Poolbeg Pharma AI model of respiratory syncytial virus starts analysis

(Alliance News) - Poolbeg Pharma PLC on Monday said its build and optimisation of an artificial intelligence model of respiratory syncytial virus data is complete.

Read more
27 May 2022 10:43

AIM WINNERS & LOSERS: Premier Miton advances; Advance Energy retreats

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
26 May 2022 16:54

IN BRIEF: Poolbeg Pharma shares soar on US patent grants

Poolbeg Pharma PLC - London-based pharmaceutical company - Wins patent grants from the US Patent & Trademark Office for its POLB 001 and POLB 002 molecules. The former is used to treat influenza, while the latter is an RNA-based immunotherapy for respiratory virus infections. "The company is continuing working with its patent advisors to broaden and expand the POLB 001 and POLB 002 patent families," Poolbeg says.

Read more
26 May 2022 10:51

AIM WINNERS & LOSERS: Poolbeg wins patents; RA swings to loss

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
12 May 2022 15:35

TRADING UPDATES: Secure Trust lending up; Eurocell sales climb

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
27 Apr 2022 20:15

IN BRIEF: Poolbeg hails shareholder confidence as lock-up period ends

Poolbeg Pharma PLC - London-based pharmaceutical company - Confirms proposals have been accepted by distribution in specie shareholders seeking to sell a total of GBP366,000 of Poolbeg shares, representing only 3% of the distribution in specie shares. Says 97% of distribution in specie shareholders have decided to remain invested in Poolbeg following the end of the lock-up period.

Read more
14 Apr 2022 21:36

TRADING UPDATES: Polar Capital assets up; Brooks Macdonald funds fall

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
14 Apr 2022 14:53

Poolbeg granted European patent for antiviral nose spray

(Sharecast News) - Clinical-stage pharmaceutical company Poolbeg Pharma reported on the strengthening of its intellectual property (IP) for its 'POLB 002' asset on Thursday - a first-in-class, intranasally-administered RNA-based immunotherapy for respiratory virus infections.

Read more
13 Apr 2022 19:46

TRADING UPDATES: McKay backs Workspace offer; IOG fixes Blythe fault

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
11 Apr 2022 21:58

TRADING UPDATES: TruFin raises GBP10 million, Afentra preferred bidder

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
11 Apr 2022 10:57

AIM WINNERS & LOSERS: Mothercare misses payment; Argos licence renewed

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
31 Mar 2022 21:07

TRADING UPDATES: SSE's Transmission raises cash; Croda gets UK grant

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
30 Mar 2022 19:25

IN BRIEF: Poolbeg Pharma starts trading on OTCQB Venture Market

Poolbeg Pharma PLC - London-based pharmaceutical company - Shares start trading on the OTCQB Venture Market in the US.

Read more
28 Mar 2022 15:10

UK shareholder meetings calendar - next 7 days

Tuesday 29 March 
Impax Asset Management Group PLCAGM
Tekmar Group PLCAGM
Wednesday 30 March 
Brunner Investment Trust PLCAGM
Mediazest PLCAGM
Micro Focus International PLCAGM
Parsley Box Group PLCGM re equity raise
Power Metal Resources PLCGM re carried forward losses
Power Metal Resources PLCAGM
Thursday 31 March 
Pressure Technologies PLCAGM
Red Rock Resources PLCAGM
Aukett Swanke Group PLCAGM
Various Eateries PLCAGM
Toople PLCAGM
BiVictriX Therapeutics PLCAGM
CloudCoCo Group PLCAGM
Friday 1 April 
Gfinity PLCGM re fundraising
River & Mercantile Group PLCAGM
Monday 4 April 
Poolbeg Pharma PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.